Correlation of TP53 mutations and p53 expression in ovarian tumors

Cancer Genetics and Cytogenetics

Volumn 105, Issue 2, 1998, Pages 93-102

  Dicioccio, Richard A ^a   Werness, Bruce A ^a   Peng, Ruoqi ^a   Allen, Howard J ^a   Piver, M S ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; NUCLEOTIDE; PROTEIN P53;

ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; OVARY TUMOR; PRIORITY JOURNAL; STOP CODON; TUMOR SUPPRESSOR GENE;

BLOTTING, WESTERN; CODON, TERMINATOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032171323     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(98)00011-9     Document Type: Article

References (71)

1. American Cancer Society (1997): Cancer Facts and Figures - 1997.
2. Weinberg R.A. The genetic origins of cancer. Cancer. 61:1988;1963-1968.
3. Sager R. Tumor suppressor genes. Science. 246:1989;1406-1412.
4. Bishop J.M. Molecular themes in carcinogenesis. Cell. 64:1991;235-248.
5. Hunter T. Cooperation between oncogenes. Cell. 64:1991;249-270.
6. Marshall C.J. Tumor suppressor genes. Cell. 64:1991;313-326.
7. Levine A. The tumor suppressor genes. Ann Rev Biochem. 62:1993;623-651.
8. Shelling A.N., Cooke I.E., Ganesan T.S. The genetic analysis of ovarian cancer. Br J Cancer. 72:1995;521-527.
9. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene. clues to cancer etiology and molecular pathogenesis Cancer Res. 54:1994;4855-4878.
10. Furihata M., Sonobe H., Ohtsuki Y. The aberrant p53 protein. Int J Oncol. 6:1995;1209-1226.
11. Gottlieb T.M., Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta. 1287:1996;77-102.
12. Soussi T. The p53 tumor suppressor gene. a model for molecular epidemiology of human cancer Mol Med Today. 2:1996;32-37.
13. DiCioccio R.A., Siniscalco M. Human RNA transcripts in man-mouse somatic cell hybrids. II. thermal denaturation studies and cot analysis Somatic Cell Genet. 1:1975;263-277.
14. Wolf D., Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL 60 cells. Proc Natl Acad Sci USA. 82:1988;790-794.
15. Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devillee P., Glover T., Collins F.S., Weston A., Modali R., Harris C.C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumour type. Nature. 342:1989;705-708.
16. Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S. Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA. 88:1991;10657-10661.
17. Orita M., Suzuki Y., Sekiya T., Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 5:1989;874-879.
18. DiCioccio R.A., Piver M.S. A polymorphism in intron 2 of the TP53 gene. Clin Genet. 50:1996;108-109.
19. Sanguinetti CJ, Neto ED, Simpson JG. Recovery and PCR amplification of DNA fragments separated on Phastgel. Pharmacia Biotech Application Note 18-1108-43.
20. Tenaud C., Negoescu A., Labat-Moleur F., Legros Y., Soussi T., Brambilla E. p53 immunolabeling in archival paraffin-embedded tissues. optimal protocol based on microwave heating for eight antibodies on lung carcinomas Methods Pathol. 7:1994;853-859.
21. DiCioccio R.A., Brown K.S. Biosynthesis, processing, and extracellular release of α-L-fucosidase in lymphoid cell lines of different genetic origins. Biochem Genet. 26:1988;401-420.
22. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
23. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. procedure and some applications Proc Natl Acad Sci USA. 76:1979;4350-4354.
24. Beudet A.L., Tsui L.C. A suggested nomenclature for designating mutations. Hum Mutat. 2:1993;245-248.
25. Marks J.R., Davidoff A.M., Kerns B.J., Humphrey P.A., Pence J.C., Dodge R.K., Clarke-Pearson D.L., Iglehart J.D., Bast R.C., Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 51:1991;2979-2984.
26. Mazars R., Pujol P., Maudelonde T., Jeanteur P., Theillet C. p53 mutations in ovarian cancer. a late event? Oncogene. 6:1991;1685-1690.
27. Okamoto A., Sameshima Y., Yokoyama S., Terashima Y., Sugimura T., Terada M., Yokota J. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res. 51:1991;5171-5176.
28. Kihana T., Tsuda H., Teshima S., Okada S., Matsuura S., Hirohashi S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res. 83:1992;978-984.
29. Mok C., Tsao S., Knapp R.C., Fishbaugh P.M., Lau C.C. Unifocal origin of advanced human epithelial ovarian cancers. Cancer Res. 52:1992;5119-5122.
30. Naito M., Satake M., Sakai E., Hirano Y., Tsuchida N., Kansaki H., Ito Y., Mori T. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res. 83:1992;1030-1036.
31. Kohler M.F., Kerns B.M., Humphrey P.A., Marks J.R., Bast R.C., Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol. 81:1993;643-650.
32. Kohler M.F., Marks J.R., Wiseman R.W., Jacobs I.J., Davidoff A.M., Clarke-Pearson D.L., Soper J.T., Bast R.C., Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst. 85:1993;1513-1519.
33. Kupryjanczyk J., Thor A.D., Beauchamp R., Merritt V., Edgerton S.M., Bell D.A., Yandell D.W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA. 90:1993;4961-4965.
34. Milner B.J., Allan L.A., Eccles D.M., Kitchener H.C., Leonard R.C.F., Kelly K.F., Parkin D.E., Haites N.E. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res. 53:1993;2128-2132.
35. Sheridan E., Hancock B.W., Goyns M.H. High incidence of mutations of the p53 gene detected in ovarian tumours by the use of chemical mismatch cleavage. Cancer Lett. 68:1993;83-89.
36. Teneriello M.G., Ebina M., Linnoila R.I., Henry M., Nash J.D., Park R.C., Birrer M.J. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 53:1993;3103-3108.
37. Fujita M., Enomoto T., Inoue M., Tanizawa O., Ozaki M., Rice J.M., Nomura T. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res. 85:1994;1247-1256.
38. McManus D.T., Yap E.P.H., Maxwell P., Russell S.E.H., Toner P.G., McGee J.O.D. p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol. 174:1994;159-168.
39. Niwa K., Itoh M., Murase T., Morishita S., Itoh N., Mori H., Tamaya T. Alteration of p53 gene in ovarian carcinoma. clinicopathological correlation and prognostic significance Br J Cancer. 70:1994;1191-1197.
40. Kappes S., Milde-Langosch K., Kressin P., Passlack B., Dockhorn-Dworniczak B., Rohlke P., Loning T. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer. 64:1995;52-59.
41. Kim J.W., Cho Y.H., Kwon D.J., Kim T.E., Park T.C., Lee J.M., Namkoong S.E. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma. Gynecol Oncol. 57:1995;199-204.
42. Klemi P.J., Pylkkanen L., Kiilholma P., Kurvinen K., Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer. 76:1995;1201-1208.
43. Kupryjanczyk J., Bell D.A., Dimeo D., Beauchamp R., Thor A.D., Yandell D.W. p53 gene analysis of ovarian borderline tumors and stage I carcinomas. Hum Pathol. 26:1995;387-392.
44. Zheng J., Benedict W.F., Xu H., Hu S., Kim T.M., Velicescu M., Wan M., Cofer K.F., Dubeau L. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J Natl Cancer Inst. 87:1995;1146-1153.
45. Wertheim I., Muto M.G., Welch W.R., Bell D.A., Berkowitz R.S., Mok S.C. p53 gene mutation in human borderline epithelial ovarian tumors. J Natl Cancer Inst. 86:1994;1549-1551.
46. Lee J., Kang Y., Park S., Kim B., Lee E., Lee K., Park K., Kavanagh J.J., Wharton J.T. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor. Cancer Genet Cytogenet. 85:1995;43-50.
47. Righetti S.C., Torre G.D., Pilotti S., Menard S., Ottone F., Colnaghi M.I., Pierotti M.A., Lavarino C., Cornarotti M., Oriana S., Bohm S., Bresciani G.L., Spatti G., Zunino F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56:1996;689-693.
48. ink4) gene alterations in human ovarian tumours. Br J Cancer. 74:1996;1069-1073.
49. Fujii T., Oguni S., Kikuchi M., Kanai N., Saito K. p53 mutation in carcinomas arising in ovarian cystic teratomas. Pathol Int. 45:1995;649-654.
50. Foulkes W.D., Stamp G.W.H., Afzal S., Lalani N., McFarlane C.P., Trowsdale J., Campbell I.G. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status. Br J Cancer. 72:1995;883-888.
51. Skilling J.S., Sood A., Nieman T., Lager D.J., Buller R.E. An abundance of p53 null mutations in ovarian cancer. Oncogene. 13:1996;117-123.
52. Runnebaum I.B., Kohler T., Stickeler E., Rosenthal H.E., Kieback D.G., Kreienberg R. p53 mutation is associated with high S-phase fraction in primary Fallopian tube adenocarcinoma. Br J Cancer. 74:1996;1157-1160.
53. Casey G., Lopez M.E., Ramos J.C., Plummer S.J., Arboleda M.J., Shaughnessy M., Karlan B., Slamon D.J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 13:1996;1971-1981.
54. Kowalski L.D., Kanbour A.I., Price F.V., Finkelstein S.D., Christopherson W.A., Seski J.C., Naus G.J., Burnham J.A., Kanbour-Shakir A., Edwards R.P. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer. 79:1997;1587-1594.
55. Provencher D.M., Lounis H., Fink D., Drouin P., Mes-Masson A.M. Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer. Tumor Biol. 18:1997;167-174.
56. Skomedal H., Kristensen G.B., Abeler V.M., Borresen-Dale A.L., Trope C., Holm R. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol. 181:1997;158-165.
57. Sood A.K., Skilling J.S., Buller R.E. Ovarian cancer genomic instability correlates with p53 frameshift mutations. Cancer Res. 57:1997;1047-1049.
58. Cariello N.F., Cui L., Beroud C., Soussi T. Database and software for analysis of mutations in the human p53 gene. Cancer Res. 54:1994;4454-4460.
59. Knudson A.G. Mutation and cancer. statistical study of retinoblastoma Proc Natl Acad Sci USA. 68:1971;820-823.
60. Hansen M.F., Cavanee W.K. Genetics of cancer predisposition. Cancer Res. 47:1987;5518-5527.
61. Moll U.M., Riou G., Levine A.J. Two distinct mechanisms alter p53 in breast cancer. mutation and nuclear exclusion Proc Natl Acad Sci USA. 89:1992;7262-7266.
62. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
63. Courjal F., Cuny M., Rodriguez C., Louason G., Speiser P., Katsaros D., Tanner M.M., Zeillinger R., Theillet C. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. Br J Cancer. 74:1996;1984-1989.
64. Mercer W.E., Baserga R. Expression of the p53 protein during the cell cycle of human peripheral blood lymphocytes. Exp Cell Res. 160:1985;31-46.
65. Hall P.A., McKee P.H., Menage H.P., Dover R., Lane D.P. High levels of p53 protein in UV-irradiated normal human skin. Oncogene. 8:1993;203-207.
66. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 8:1993;307-318.
67. Eeles R.A., Warren W., Knee G., Bartek J., Averill D., Stratton M.R., Blake P.R., Tait D.M., Lane D.P., Easton D.F., Yarnold J.R., Cooper C.S., Sloane J.P. Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours. molecular and immunohistochemical findings Oncogene. 8:1993;1269-1276.
68. Ciechanover A., DiGiuseppe J.A., Bercovich B., Orian A., Richter J.D., Schwartz A.L., Brodeur G.M. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci USA. 88:1991;139-143.
69. Wynford-Thomas D. p53 in tumour pathology. can we trust immunocytochemistry? J Pathol. 166:1992;329-330.
70. Hall P.A., Lane D.P. p53 in tumour pathology. can we trust immunohistochemistry? - revisited J Pathol. 172:1994;1-4.
71. Sjogren S., Inganas M., Norberg T., Lindgren A., Nordgren H., Holmberg L., Bergh J. The p53 gene in breast cancer. prognostic value of complementary DNA sequencing versus immunohistochemistry J Natl Cancer Inst. 88:1996;173-182.